A. FUSARI, ET AL 56. Quinn NP, Rossor MN, Marsden CD. Olfactory threshold in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1987; 50: 88-9. 57. Ward CD, Hess WA, Calne DB. Olfactory impairment in Parkinson’s disease. Neurology 1983; 33: 943-6. 58. Corwin J, Serby M, Conrad P, Rotrosen J. Olfactory recognition deficit in Alzheimer’s and parkinsonian dementias. IRCS Med Sci 1985; 13: 260. 59. Morgan CD, Nordin S, Murphy C. Odor identification as an early marker for Alzheimer’s disease: impact of lexical functioning and detection sensitivity. J Clin Exp Neuropsychol 1995; 17: 793-803. 60. Rezek DL. Olfactory deficits as a neurologic sign in dementia of the Alzheimer type. Arch Neurol 1987; 44: 1030-2. 61. Warner M, Peabody C, Flattery J, Tinklenberg J. Olfactory deficits and Alzheimer’s disease. Biol Psychiatry 1986; 21: 116-8. 62. Serby M, Mohan C, Aryan M, Williams L, Mohs RC, Davis KL. Olfactory identification deficits in relatives of Alzheimer’s disease patients. Biol Psychiatry 1996; 39: 375-7. 63. Youssem DM, Turner WJ, Li C, Snyder PJ, Doty RL. Kallmann syndrome: MR evaluation of olfactory system. AJNR Am J Neuroradiol 1993; 14: 839-43. 64. Cowen MA, Green M. IL-1b and Kallmann’s syndrome: a variant model of schizophrenia? Biol Psychiatry 1993; 33: 71-2. 65. Brody D, Serby M, Etienne N, Kalkastein D. Olfactory identification deficits in HIV infection. Am J Psychiatry 1991; 148: 248-50. 66. West SE, Doty RL. Influence of epilepsy and temporal lobe resection on olfactory function. Epilepsia 1995; 36: 531-42. 67. Moreno-Martínez FJ, Tallón-Barranco A, Frank-García A. Enfermedad de Alzheimer, deterioro categorial y variables relevantes en la denominación de objetos. Rev Neurol 2007; 44: 129-33. 68. Tabaton M, Cammarata S, Mancardi GL, Cordone G, Perry G, Loeb C. Abnormal tau-reactive filaments in olfactory mucosa in biopsy specimens of patients with probable Alzheimer’s disease. Neurology 1991; 41: 391-4. 69. Kaakkola S, Palo J, Malmberg H, Sulkava R, Virtanen I. Neurofilament profile in olfactory mucosa of patients with a clinical diagnosis of Alzheimer’s disease. Virchows Arch 1994; 424: 315-9. 70. Talamo BR, Rudel R, Kosik KS, Lee VMY, Net S, Adelman L, et al. Pathological changes in olfactory neurons in patients with Alzheimer’s disease. Nature 1989; 337: 736-9. 71. Hock C, Golombowski S, Mullerspahn F, Peschel O, Riederer A, Probst A, et al. Histological markers in nasal mucosa of patients with Alzheimer’s disease. Eur Neurol 1998; 40: 31-6. 72. Kovács T, Cairns NJ, Lantos PL. β-amyloid deposition and neurofibrillary tangle formation in the olfactory bulb in ageing and Alzheimer’s disease. Neuropathol Appl Neurobiol 1999; 25: 481-91. 73. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239-9. 74. Kovács T, Cairns NJ, Lantos PL. Olfactory centres in Alzheimer’s disease: olfactory bulb is involved in early Braak’s stages. Neuroreport 2001; 12: 285-8. 75. Murphy C, Cerf-Ducastel B, Calhoun-Haney R, Gilbert PE, Ferdon S. EPR, fMRI and functional connectivity studies of brain response to odor in normal aging and Alzheimer’s disease. Chem Senses 2005; 30: 170-1. 76. Tabert MH, Steffener JR, Albers MW, Devanand DP. P-062 Neural correlates of olfactory deficits in Alzheimer’s disease patients: an fMRI study. Alzheimer’s and Dementia 2007; 3: S118. 77. Buchsbaum MS, Kesslak JP, Lynch G, Chui H, Wu J, Sicotte N, et al. Temporal and hippocampal metabolic rate during an olfactory memory task assessed by positron emission tomography in patients with dementia of the Alzheimer type and control. Preliminary studies. Arch Gen Psychiatry 1991; 48: 840-7. 78. Kareken DA, Doty RL, Moberg PJ, Mosnik D, Chen SH, Farlow MR, et al. Olfactory-evoked regional cerebral blood flow in Alzheimer’s disease. Neuropsychology 2001; 15: 18-29. 79. Murphy C, Gilmore MM, Seery CS, Salmon DP, Lasker BR. Olfactory thresholds are associated with degree of dementia in Alzheimer’s disease. Neurobiol Aging 1990; 11: 465-9. 80. Corwin J, Serby M. Olfactory recognition deficit in Alzheimer’s and Parkinsonian dementias. IRCS Med Sci 1985; 13: 260. 81. Knupfer L, Spiegel R. Differences in olfactory test performance between normal aged, Alzheimer and vascular type dementia individuals. Int J Geriatr Psychiatry 1986; 1: 3-14. 82. Nordin S, Almkvist O, Berglund B, Wahlund LO. Olfactory dysfunction for pyridine and dementia progression in Alzheimer disease. Arch Neurol 1997; 54: 993-8. 83. Richard J, Bizzini L. Olfaction et démences. Premiers résultats d’une étude clinique et expérimentale avec le n-propanol. Acta Neurol Belg 1981; 81: 833-51. 84. Serby M, Corwin J, Conrad P, Rotrosen J. Olfactory dysfunction in Alzheimer’s disease and Parkinson’s disease. Am J Psychiatry 1985; 142: 781-2. 368 85. Nordin S, Monsch AU, Murphy C. Unawareness of smell loss in normal aging and Alzheimer’s disease: discrepancy between self-reported and diagnosed smell sensitivity. J Gerontol 1995; 50: 187-92. 86. Doty RL, Reyes PF, Gregor T. Presence of both odor identification and detection deficits in Alzheimer’s disease. Brain Res Bull 1987; 18: 597-600. 87. Wilson RS, Arnold SE, Schneider JA, Tang Y, Bennett DA. The relationship between cerebral Alzheimer’s disease pathology amd odour identification in old age. J Neurol Neurosurg Psychiatry 2007; 78: 30-5. 88. Schiffman SA, Clark CM, Warwick Z. Gustatory and olfactory dysfunction in dementia: not specific to Alzheimer’s disease. Neurobiol Aging 1990; 11: 597-600. 89. McCaffrey RJ, Duff K, Solomon GS. Olfactory dysfunction discriminates probable Alzheimer’s dementia from major depression: a crossvalidation and extension. J Neuropsychiatr Clin Neurosci 2000; 12: 29-33. 90. Solomon GS, Petrie WM, Hart JR, Brackin HB Jr. Olfactory dysfunction discriminates Alzheimer’s dementia from major depression. J Neuropsychiatr Clin Neurosci 1998; 10: 64-7. 91. De Rijk MC, Tzourio C, Breteler MM, Dartigues JF, Amaducci L, LópezPousa S, et al. Prevalence of parkinsonism and Parkinson’s disease in Europe: the EuroParkinson Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson’s disease. J Neurol Neurosurg Psychiatry 1997; 62: 105. 92. Allam MF, Del Castillo AS, Navajas RF. Factores de riesgo en la enfermedad de Parkinson. Rev Neurol 2003; 36: 749-55. 93. Doty RL, Deems DA, Stellar S. Olfactory dysfunction in Parkinsonism: a general deficit unrelated to neurologic signs, disease stage, or disease duration. Neurology 1988; 38: 1237-44. 94. Müller A, Müngersdorf M, Reichmann H, Strehle G, Hummel T. Olfactory function in Parkinsonian syndromes. J Clin Neurosci 2002; 9: 521-4. 95. Müller A, Reichmann H, Livermore A, Hummel T. Olfactory function in idiopathic Parkinson’s disease (IPD): results from cross-sectional studies in IPD patients and long-term follow-up of de-novo IPD patients. J Neural Transm 2002; 109: 805-11. 96. Wenning GK, Shephard B, Hawkes C, Petruckevitch A, Lees A, Quinn N. Olfactory function in atypical Parkinsonian syndromes. Acta Neurol Scand 1995; 91: 247-50. 97. Westervelt HJ, Stern RA, Tremont G. Odor identification deficits in diffuse Lewy body disease. Cogn Behav Neurol 2003; 16: 93-9. 98. Sims KS, Williams RS. The human amygdaloid complex. A cytologic and histochemical atlas using Nissl, myelin, acetylcholinesterase and nicotinamide adenine dinucleotide phosphate diaphorase staining. Neuroscience 1990; 36: 449-72. 99. Gloor P. The amygdaloid system. In Gloor P, ed. The temporal lobe and the limbic system. New York: Oxford University Press; 1997; p. 591-721. 100. Braak H, Braak E, Yilmazer D, De Vos R, Jansen E, Bohl J, et al. Amygdala pathology in Parkinson’s disease. Acta Neuropathol 1994; 88: 493-500. 101. Daniel SE, Hawkes CH. Preliminary diagnosis of Parkinson’s disease by olfactory bulb pathology. Lancet 1992; 340: 186. 102. Hawkes CH, Shephard BC, Daniel SE. Olfactory dysfunction in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1997; 62: 436-6. 103. Braak H, Rüb U, Gai WP, Del Tredici K. Idiopathic Parkinson’s disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm 2003; 110: 517-36. 104. Doty RL, Riklan M, Deems DA, Reynolds C, Stellar S. The olfactory and cognitive deficits of Parkinson’s disease: evidence for independence. Ann Neurol 1989; 25: 166-71. 105. Doty RL, Singh A, Tetrud J, Langston JW. Lack of major olfactory dysfunction in MPTP-induced Parkinsonism. Ann Neurol 1992; 32: 97-100. 106. Doty RL, Stern MB, Pfeiffer C, Gollomp SM, Hurtig HI. Bilateral olfactory dysfunction in early stage treated and untreated idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 1992; 55: 138-42. 107. Quinn NP, Ressor MN, Marsden CD. Olfactory threshold in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1987; 50: 88-9. 108. Roth J, Radil T, Ruzicka E, Jech R, Tichy J. Apomorphine does not influence olfactory thresholds in Parkinson’s disease. Funct Neurol 1998; 13: 99-103. 109. Tissingh G, Berendse HW, Bergmans P, DeWaard R, Drukarch B, Stoof JC, et al. Loss of olfaction in de novo and treated Parkinson’s disease: possible implications for early diagnosis. Mov Disord 2001; 16: 41-6. 110. Stern MB, Doty RL, Dotti M, Corcoran P, Crawford D, McKeown DA, et al. Olfactory function in Parkinson’s disease subtypes. Neurology 1994; 44: 266-8. 111. Fusari A, Molina JA. <strong>Olfato</strong>, <strong>envejecimiento</strong> <strong>fisiológico</strong> y <strong>enfermedades</strong> <strong>neurodegenerativas</strong>: I. Anatomía y exploración clínica. Rev Neurol 2009; 49: 321-6. REV NEUROL 2009; 49 (7): 363-369
OLFATO Y ENVEJECIMIENTO SENSE OF SMELL, PHYSIOLOGICAL AGEING AND NEURODEGENERATIVE DISEASES: II. AGEING AND NEURODEGENERATIVE DISEASES Summary. Introduction. The sense of smell, which was once studied because of its biological and evolutionary significance, is today one of the centres of interest in research on normal and pathological ageing. The latest scientific developments point to an inversely proportional relationship between age and olfactory sensitivity. In certain neurodegenerative diseases this sensory decline is one of the first symptoms of the disorder and is correlated with the progression of the disease. Development. In this work we are going to review the scientific knowledge on loss of sense of smell in ageing and in neurodegenerative diseases, with special attention given to Alzheimer’s and Parkinson’s diseases. Conclusions. A survey of studies that have examined the olfactory deficits in ageing and in some neurodegenerative diseases offers conclusive results about the presence of these impairments in the early stages of these disorders and even among healthy elderly persons. Although a number of causes contribute to these sensory losses in physiological ageing, a common neurological foundation has been proposed for Alzheimer's and Parkinson’s diseases. Nevertheless, despite certain initial similarities, the olfactory deficits shown in these disorders seem to be qualitatively different. [REV NEUROL 2009; 49: 363-9] Key words. Ageing. Alzheimer’s disease. Neurodegenerative disease. Olfactory tests. Parkinson’s disease. Sense of smell. REV NEUROL 2009; 49 (7): 363-369 369
Change language